119th Congress · introduced in the Senate · Mar 11, 2025
Give Kids a Chance Act of 2025
Official title from Congress.gov
Latest action (Mar 11, 2025): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in Senate (Mar 11, 2025)
Give Kids a Chance Act of 2025
This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer, and renews the Food and Drug Administration’s (FDA’s) authority to award priority review vouchers (PRVs) to sponsors of new products for rare pediatric diseases.
Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs used in combination with active ingredients that have already been approved and that (1) have been determined to be part of the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.
The FDA must issue guidance on the implementation of these provisions and report to Congress on its efforts to ensure implementation. The Government Accountability Office (GAO) must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.
The bill also renews the FDA’s authority to issue PRVs to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029. This is known as the Rare Pediatric Disease PRV program. The program expired in December 2024.
GAO must report on the effectiveness of the Rare Pediatric Disease PRV program, including to what extent PRVs were successful in promoting drug development and expediting patient access to drugs for the treatment or prevention of rare pediatric diseases.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
198 citations; showing the 25 most recently posted.
NATIONWIDE CHILDREN'S HOSPITAL INC · lobbying firm or registrant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$57,000
Spent on own lobbying
…ealth and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025 S. 1677 Ensuring Lasting Smiles Act S. 2372 340B PATIENTS Act S. 5037 MediKids Act S. 5244 Sustain 340B Act H.R. 10770 340B Reba…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONWIDE CHILDREN'S HOSPITAL INC · lobbying firm or registrant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Medicare/Medicaid
$57,000
Spent on own lobbying
…ealth and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025 S. 1677 Ensuring Lasting Smiles Act S. 2372 340B PATIENTS Act S. 5037 MediKids Act S. 5244 Sustain 340B Act H.R. 10770 340B Reba…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.) · lobbying firm or registrant: NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$1,520,000
Spent on own lobbying
…Infrastructure Act Issues related Pub. L No. 119-21; specifically state direct payments. H.R. 3890, Resident Physician Shortage Reduction Act of 2025 H.R. 1262/S.932, Give Kids a Chance Act H.R. 3505, Barriers to Suicide Act H.R. 4262, To reauthorize programs related to health professions education, and for other purposes.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.) · lobbying firm or registrant: NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$1,520,000
Spent on own lobbying
…supplemental payments and directed payments. Issues regarding out of state care for children enrolled in Medicaid. Issues regarding Hospital at Home H.R. 1262/S.932 Give Kids a Chance Act H.R. 1509/S. 752 Accelerating Kids Access to Care Act Issues related Pub. L No. 119-21; specifically state directed payments.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PTC THERAPEUTICS, INC. · lobbying firm or registrant: LMH STRATEGIC SOLUTIONS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
…n Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
IONIS PHARMACEUTICALS, INC. · lobbying firm or registrant: LMH STRATEGIC SOLUTIONS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$30,000
Paid to lobbying firm
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTCT · lobbying firm or registrant: SMITHBUCKLIN CORPORATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
…nce Oversight H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act S. 4440/H.R. 3521 - The Clinical Trial Modernization Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
IONIS PHARMACEUTICALS, INC. · lobbying firm or registrant: IONIS PHARMACEUTICALS, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$150,000
Spent on own lobbying
Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025. Issues related to drug pricing policy.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CURE SMA · lobbying firm or registrant: CURE SMA
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 13, 2026 · issue area: Health Issues
$75,000
Spent on own lobbying
…ts, medical devices, and home and community-based services, Medicaid home care (paid family caregiving & self-directed care), Give Kids a Chance Act (H.R.1261/ S.932- FDA Pediatric Priority Review Voucher Program), DOD Congressionally Directed Medical Research Program & Peer-Reviewed Medical Research Program, Local Coverage…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HEALTHCARE INSTITUTE OF NEW JERSEY · lobbying firm or registrant: HEALTHCARE INSTITUTE OF NEW JERSEY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 7, 2026 · issue area: Health Issues
$49,416
Spent on own lobbying
…er and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 i…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
LIFE SCIENCES PENNSYLVANIA · lobbying firm or registrant: LIFE SCIENCES PENNSYLVANIA
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 6, 2026 · issue area: Science/Technology
$6,000
Spent on own lobbying
…tended to September 30, 2029. The full US House of Representatives has not yet voted on this legislation. The Senate version of Give Kids a Chance Act of 2025 (S.932) was introduced in March and is awaiting any movement from the Senate HELP Committee.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BAYER CORPORATION (CONSOLIDATED REPORT) · lobbying firm or registrant: BAYER CORPORATION (CONSOLIDATED REPORT)
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · amended · posted Aug 31, 2026 · issue area: Health Issues
$2,040,000
Spent on own lobbying
…nerally recognized as safe (GRAS) rules for food additives. H.R. 1262, Give Kids a Chance Act of 2025. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. S. 932, Give Kids a Chance Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BAYER CORPORATION (CONSOLIDATED REPORT) · lobbying firm or registrant: BAYER CORPORATION (CONSOLIDATED REPORT)
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · amended · posted Aug 31, 2026 · issue area: Health Issues
$1,760,000
Spent on own lobbying
…ne quotas. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). H.R. 1262, Give Kids a Chance Act of 2025. S. 932, Give Kids a Chance Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
STEALTH BIOTHERAPEUTICS INC. · lobbying firm or registrant: STEALTH BIOTHERAPEUTICS INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$120,000
Spent on own lobbying
H.R. 1262/S. 932 - Mikaela Naylon Give Kids a Chance Act General discussions about ultra-rare diseases General discussions about ultra-rare disease drug development General dis…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.) · lobbying firm or registrant: NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$1,370,000
Spent on own lobbying
…Infrastructure Act Issues related Pub. L No. 119-21; specifically state direct payments. H.R. 3890, Resident Physician Shortage Reduction Act of 2025 H.R. 1262/S.932, Give Kids a Chance Act H.R. 3505, Barriers to Suicide Act H.R. 4262, To reauthorize programs related to health professions education, and for other purposes.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.) · lobbying firm or registrant: NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$1,370,000
Spent on own lobbying
…hare Hospitals (DSH) and directed payments. Issues regarding out of state care for children enrolled in Medicaid. Issues related to Hospital at Home. H.R. 1262/S.932 Give Kids a Chance Act H.R. 1509/S. 752 Accelerating Kids Access to Care Act Issues related Pub. L No. 119-21; specifically state directed payments.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TOURETTE ASSOCIATION OF AMERICA · lobbying firm or registrant: TOURETTE ASSOCIATION OF AMERICA
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$60,000
Spent on own lobbying
…1261 - Connect for Health Act of 2025) H.R. 3514/S.1816- Improving Seniors Timely Access to Care Act of 2025 H.R. 5509/S. 2903- Safe Step Act of 2025 H.R. 1262/S. 932- Give Kids a Chance Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NOVARTIS · lobbying firm or registrant: NOVARTIS
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$1,410,000
Spent on own lobbying
…g and Ensuring PBM Accountability (MEPA) Act Coverage of Accelerated Approval Products Drug Benefit Design Orphan Drug Issues S. 1682/H.R.946: ORPHAN Cures Act S.932/H.R. 1262: Give Kids a Chance Act of 2025 Innovation in Pediatric Drugs Act S.864: HELP Copays Act Reimbursement and Coverage of Innovative Products Lower Cost…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTCT · lobbying firm or registrant: SMITHBUCKLIN CORPORATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
…larifications H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act S. 4440/H.R. 3521 - The Clinical Trial Modernization Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
IONIS PHARMACEUTICALS, INC. · lobbying firm or registrant: IONIS PHARMACEUTICALS, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Health Issues
$150,000
Spent on own lobbying
Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025. Issues related to drug pricing policy.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AQUESTIVE THERAPEUTICS · lobbying firm or registrant: BRACEWELL LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 16, 2026 · issue area: Health Issues
$60,000
Paid to lobbying firm
Give Kids a Chance Act (H.R.1262),(S.932) and other issues related to therapeutics
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · lobbying firm or registrant: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 16, 2026 · issue area: Health Issues
$60,000
Paid to lobbying firm
Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONWIDE CHILDREN'S HOSPITAL INC · lobbying firm or registrant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 15, 2026 · issue area: Health Issues
$80,000
Spent on own lobbying
…ealth and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025 S. 1677 Ensuring Lasting Smiles Act S. 2372 340B PATIENTS Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONWIDE CHILDREN'S HOSPITAL INC · lobbying firm or registrant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 15, 2026 · issue area: Medicare/Medicaid
$80,000
Spent on own lobbying
…ealth and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025 S. 1677 Ensuring Lasting Smiles Act S. 2372 340B PATIENTS Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HEALTHCARE INSTITUTE OF NEW JERSEY · lobbying firm or registrant: HEALTHCARE INSTITUTE OF NEW JERSEY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 15, 2026 · issue area: Health Issues
$47,670
Spent on own lobbying
…er and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 i…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing